CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $261.27M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
229.15MEUR261.27M · vs all stocks (USD)
Revenue (TTM)
15.41MEUR17.57M · vs all stocks (USD)
Profit Margin
-15.76%vs Biotechnology peers
Beta
0.4370xvs all stocks
52-Week Change
-16.07%vs all stocks
Market Capitalization
229.15MEUR261.27M · vs all stocks (USD)
Enterprise Value
211.30MEUR240.91M · vs all stocks (USD)
Forward P/E
308.44xvs Biotechnology peers
Price to Sales (TTM)
14.77xvs Biotechnology peers
Price to Book (MRQ)
1.80xvs Biotechnology peers
Enterprise to Revenue
13.71xvs Biotechnology peers
Enterprise to EBITDA
-36.17xvs Biotechnology peers
Profit Margin
-15.76%vs Biotechnology peers
Operating Margin
30.77%vs Biotechnology peers
Return on Assets (TTM)
-2.66%vs Biotechnology peers
Return on Equity (TTM)
-2.08%vs Biotechnology peers
Revenue (TTM)
15.41MEUR17.57M · vs all stocks (USD)
Revenue per Share (TTM)
0.1990EURUpdated Sep 23, 2026Quarterly Revenue Growth
106.00%vs Biotechnology peers
Gross Profit (TTM)
15.06MEUR17.17M · vs all stocks (USD)
EBITDA (TTM)
-5.84MEUR-6.66M · vs all stocks (USD)
Net Income (TTM)
-2.43MEUR-2.77M · vs all stocks (USD)
Operating Cash Flow (TTM)
-4.91MEUR-5.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-16.36MEUR-18.66M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Sep 23, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00EURFY2025 · Dec 31, 2025Cost of Goods Sold
-10.65MEURFY2025 · Dec 31, 2025Gross Profit
10.65MEURFY2025 · Dec 31, 2025Operating Income
-5.71MEUR-6.51M · vs all stocks (USD)
Pre-tax Income
-5.60MEURFY2025 · Dec 31, 2025Income Tax Expense
-2.99MEURFY2025 · Dec 31, 2025Net Income
-2.61MEURFY2025 · Dec 31, 2025EBIT
-4.99MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-4.81MEURFY2025 · Dec 31, 2025Other Operating Expenses
12.42MEURFY2025 · Dec 31, 2025Non-operating Interest Income
713.27KEURFY2025 · Dec 31, 2025Non-operating Interest Expense
608.34KEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
-6.19MEURFY2025 · Dec 31, 2025Free Cash Flow
-6.25MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
28.35MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-5.60MEURFY2025 · Dec 31, 2025Other Non-cash Items
-79.93KEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-299.33KEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-215.76KEURFY2025 · Dec 31, 2025Capital Expenditures
-59.39KEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-10.98MEURFY2025 · Dec 31, 2025Purchase of Investments
0.00EURFY2025 · Dec 31, 2025Sale of Investments
1.86KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-57.54KEURFY2025 · Dec 31, 2025Long-term Debt Issuance
14.49MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-11.37MEURFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-4.69MEURFY2025 · Dec 31, 2025Common Stock Repurchase
0.00EURFY2025 · Dec 31, 2025Other Financing Charges
4.36MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
31.44MEURFY2025 · Dec 31, 2025Shares Outstanding
81.96MSharesUpdated Sep 23, 2026Float Shares
61.45MSharesUpdated Sep 23, 2026% Held by Insiders
20.97%vs all stocks
% Held by Institutions
1.83%vs all stocks
Total Cash (MRQ)
14.69MEUR16.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1890EURUpdated Sep 23, 2026Total Debt (MRQ)
10.80MEUR12.31M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0902xvs Biotechnology peers
Current Ratio (MRQ)
1.60xvs Biotechnology peers
Book Value per Share (MRQ)
1.54EURUpdated Sep 23, 2026Total Assets
144.52MEUR164.78M · vs all stocks (USD)
Total Current Assets
30.67MEURFY2025 · Dec 31, 2025Total Liabilities
26.68MEURFY2025 · Dec 31, 2025Total Non-current Assets
113.86MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
10.91MEURFY2025 · Dec 31, 2025Total Current Liabilities
15.77MEURFY2025 · Dec 31, 2025Cash
25.35MEURFY2025 · Dec 31, 2025Cash Equivalents
3.00MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
28.35MEURFY2025 · Dec 31, 2025Other Short-term Investments
14.58KEURFY2025 · Dec 31, 2025Accounts Receivable
106.57KEURFY2025 · Dec 31, 2025Inventory
3.73KEURFY2025 · Dec 31, 2025Accounts Payable
2.75MEURFY2025 · Dec 31, 2025Short-term Debt
4.55MEURFY2025 · Dec 31, 2025Long-term Debt
3.08MEURFY2025 · Dec 31, 2025Common Stock (Book)
3.99MEURFY2025 · Dec 31, 2025Retained Earnings
-20.81MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
117.85MEUR134.36M · vs all stocks (USD)
Treasury Stock
5.81MEURFY2025 · Dec 31, 202552-Week Low
2.60EURUpdated Sep 23, 202652-Week High
4.02EURUpdated Sep 23, 202652-Week Change
-16.07%vs all stocks
Beta
0.4370xvs all stocks
50-Day MA
2.86EURUpdated Sep 23, 2026200-Day MA
2.97EURUpdated Sep 23, 2026Avg 10-Day Volume
79.93KSharesUpdated Sep 23, 2026Avg 30-Day Volume
129.92KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
-0.0300EURUpdated Sep 23, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.56
Altman Z-Score 4.96: safe zoneNotable
Altman Z-Score: 4.96
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $261.27M, lower than 95% of all stocks globallySignificant
Market cap (USD): 261,266,643.938Global P5: 275,556,405.438
Revenue is $17.57M, lower than 95% of all stocks globallySignificant
Revenue (USD): 17,566,382.11Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Lineage Cell Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anhui Tatfook Technology Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Hebei Sailhero Environmental Protection Hi-Tech Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Finolex Industries Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity